Announced details
Investigator-initiated clinical trial for aggressive NK-cell leukemia
The company will receive a subsidy. Capital relationship, personnel relationship, and ordinary business relationship: not disclosed.
An incorporated administrative agency responsible for the FY2026 Drug Discovery Support Promotion Project and the Practical Application Support Project for Orphan Drugs Before Designation. Location, representative, capital, and year established: not disclosed.
¥100 million (approved grant amount)
The impact on results for the fiscal year ending March 2027 is expected to be minor.
The company does not address Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | PPMX-T003 (treatment for aggressive NK-cell leukemia) |
| Counterparty | Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | An incorporated administrative agency responsible for the FY2026 Drug Discovery Support Promotion Project and the Practical Application Support Project for Orphan Drugs Before Designation. Location, representative, capital, and year established: not disclosed. |
| Relationship with the Company | The company will receive a subsidy. Capital relationship, personnel relationship, and ordinary business relationship: not disclosed. |
| Contract Value | ¥100 million (approved grant amount) |
| Applicable area | Investigator-initiated clinical trial for aggressive NK-cell leukemia |
| Impact on Business Performance | The impact on results for the fiscal year ending March 2027 is expected to be minor. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This support is provided under the FY2026 Drug Discovery Support Promotion Project and the Practical Application Support Project for Orphan Drugs Before Designation, administered by the Japan Agency for Medical Research and Development (AMED), and will be used to cover the costs of conducting the investigator-initiated clinical trial of PPMX-T003 for aggressive NK-cell leukemia.